SCHEMBL9902431

SCHEMBL9902431

NC[CH]c1ccc(Cl)c(Cl)c1C(N)=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 3/20 0.35
▸ PLK4 O00444 3/20 0.35
▸ DYRK3 O43781 3/20 0.35
▸ ROCK2 O75116 3/20 0.35
▸ PRKD3 O94806 3/20 0.35
▸ MAP4K4 O95819 3/20 0.35
▸ INSR P06213 3/20 0.35
▸ CDK1 P06493 3/20 0.35
▸ PIM1 P11309 3/20 0.35
▸ FGFR1 P11362 3/20 0.35
▸ PRKACA P17612 3/20 0.35
▸ RPS6KB1 P23443 3/20 0.35
▸ CDK2 P24941 3/20 0.35
▸ KDR P35968 3/20 0.35
▸ CSNK1A1 P48729 3/20 0.35
▸ CSNK1D P48730 3/20 0.35
▸ CLK2 P49760 3/20 0.35
▸ GSK3B P49841 3/20 0.35
▸ IRAK1 P51617 3/20 0.35
▸ LIMK1 P53667 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12497303 0.87 CDC7 (0.34) CDC7PLK4DYRK3ROCK2PRKD3
SCHEMBL12497720 0.86 CDC7 (0.35) CDC7PLK4DYRK3ROCK2PRKD3
SCHEMBL16649255 0.83 CDC7 (0.34) CDC7PLK4DYRK3ROCK2PRKD3
SCHEMBL16649116 0.81 CDC7 (0.33) CDC7PLK4DYRK3ROCK2PRKD3
SCHEMBL9903830 0.79 ALDH1A1 (0.42) KMT2APBRM1
SCHEMBL16650033 0.79 CDC7 (0.32) CDC7PLK4DYRK3ROCK2PRKD3
SCHEMBL16649590 0.75 NOTUM (0.33) CDC7PLK4DYRK3ROCK2PRKD3
SCHEMBL16649634 0.74 CDC7 (0.33) CDC7PLK4DYRK3ROCK2PRKD3
SCHEMBL15129326 0.72 CDC7 (0.33) CDC7PLK4DYRK3ROCK2PRKD3
SCHEMBL12497243 0.71 PBRM1 (0.35) KMT2AATMPBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 — — EP claimed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 — — US claimed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 — — US claimed
EP-2462141-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS Merck Patent GmbH (DE) 2012-06-13 — — EP claimed
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 — — EP disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 — — US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277228-A1 Novel Azaheterocyclic Compounds PCNA, MCL1, MYC CDC7 81/4885PLK4 2150/4885DYRK3 4085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback